AI Transformation Strategy : The AI transformation isn’t coming. It’s already here. While some organizations are leveraging AI to drive unprecedented growth and efficiency, others are falling behind, …
The biopharmaceutical industry stands at the intersection of groundbreaking innovation and stringent regulatory compliance.
Predictive analytics applied to determining non-conformities in the pharmaceutical industry represents a significant advancement in ensuring product quality and safety.
Artificial intelligence (AI) rapidly transforms the biopharmaceutical industry, offering unprecedented opportunities to enhance efficiency, accuracy, and innovation. However, as AI becomes increasingly integrated into GMP-regulated processes, traditional quality management approaches must be rethought. This article delves into the critical aspects of GMP quality compliance in the AI era. It explores the top five reasons why
Computerized System Assurance (CSA) is a modern approach to validating automated systems, particularly in the life sciences industry. It emphasizes a risk-based methodology, focusing on product quality and patient safety, rather than the traditional, more burdensome Computer System Validation (CSV) approach [1], [2]. This article delves into the intricacies of CSA, highlighting the dos and